5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO(3,4-f) QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS

Details for Australian Patent Application No. 2003258051 (hide)

Owner LIGAND PHARMACEUTICALS INCORPORATED

Inventors VAN OEVEREN, Cornelis, Arjan; PEDRAM, Bijan; KARANEWSKY, Donald; ZHI, Lin

Pub. Number AU-A-2003258051

PCT Number PCT/US03/24420

PCT Pub. Number WO2004/033461

Priority 60/417,968 11.10.02 US

Filing date 4 August 2003

Wipo publication date 4 May 2004

International Classifications

C07D 491/04 Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or

A61K 031/436

A61P 035/00 Antineoplastic agents

A61P 015/18 Drugs for genital or sexual disorders

Event Publications

13 November 2003 Complete Application Filed

  Priority application(s): 60/417,968 11.10.02 US

3 June 2004 Application Open to Public Inspection

  Published as AU-A-2003258051

30 June 2005 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003258052-SEMANTIC QUALIFICATION AND CONTEXTUALIZATION OF ELECTRONIC MESSAGES

2003258050-5-CYCLOALKENYL 5H-CHROMENO(3,4-F)QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS